BEAM - Beam Therapeutics Inc.

31.19
-0.200   -0.641%

Share volume: 1,249,571
Last Updated: 04-20-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$31.39
-0.20
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 8%
Dept financing 9%
Liquidity 43%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.84%
1 Month
23.92%
3 Months
0.22%
6 Months
4.35%
1 Year
71.00%
2 Year
29.42%
Key data
Stock price
$31.19
P/E Ratio 
0.00
DAY RANGE
$30.61 - $31.46
EPS 
-$0.90
52 WEEK RANGE
$15.35 - $36.44
52 WEEK CHANGE
$63.04
MARKET CAP 
2.813 B
YIELD 
N/A
SHARES OUTSTANDING 
101.856 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.99
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,048,713
AVERAGE 30 VOLUME 
$2,155,200
Company detail
CEO: John Evans
Region: US
Website: beamtx.com
Employees: 510
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

Recent news